Kyowa Kirin and LEO Pharma terminate collaboration on Dovobet
Denmark’s privately-held dermatology specialist LEO Pharma and Japan’s Kyowa Kirin (TYO: 4151) have revealed that they will terminate the distribution and co-promotion agreement for the psoriasis vulgaris treatment Dovobet Ointment, Gel, and Foam (calcipotriol hydrate / betamethasone dipropionate) in Japan on December 31, 2024.
Kyowa Kirin, LEO Pharma, and its parent company LEO Pharma A/S entered into a distribution and co-promotion agreement for Dovobet in December 2013. Under this agreement, LEO Pharma has been responsible for product production and sales, while Kyowa Kirin has handled sales and provided medical information to healthcare professionals via its medical representatives.
Both marketing activities have been jointly conducted by LEO Pharma and Kyowa Kirin. With the termination of this agreement, Kyowa Kirin's sales of Dovobet will be suspended on December 31, 2024.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze